SEARCH:   Advanced

Blood, 15 August 2008, Vol. 112, No. 4, pp. 990-998. Prepublished online as a Blood First Edition Paper on April 21, 2008; DOI 10.1182/blood-2007-12-130179. This Article Full Text (PDF) All Versions of this Article: blood-2007-12-130179v1 112/4/990    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Devine, S. M Articles by DiPersio, J. F Search for Related Content PubMed PubMed Citation Articles by Devine, S. M Articles by DiPersio, J. F Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 19, 2007 Accepted April 7, 2008 Rapid mobilization of functional donor hematopoietic cells without G-CSF using plerixafor, an antagonist of the CXCR4/SDF-1 interaction Steven M Devine*, Ravi Vij, Michael Rettig, Laura Todt, Kiley McGlauchlen, Nicholas Fisher, Hollie Devine, Daniel C Link, Gary Calandra, Gary Bridger, Peter Westervelt, and John F DiPersio Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States Medicine, Washington University, St Louis, Missouri, United States Genzyme Inc, Genzyme Inc, Cambridge, MA, United States * Corresponding author; email: steven.devine{at}osumc.edu. Allografts from HLA-matched sibling donors were mobilized and collected without G-CSF using Plerixafor (AMD3100), a direct antagonist of CXCR4/SDF-1. Donors (N=25) were treated with AMD3100 at a dose of 240 µg/kg by subcutaneous injection and leukapheresis was then initiated just 4 hours later. Two-thirds of the donors collected an allograft with a CD34+ cell dose sufficient for transplantation after just one dose of AMD3100. No donor experienced more than grade one toxicity. Following a myeloablative regimen, twenty patients with hematological malignancies received allografts collected after AMD3100 alone. All patients engrafted neutrophils (median day +10) and platelets (median day +12) promptly. Acute GVHD grades 2-4 occurred in 35% of patients. One patient died due to complications related to acute GVHD. No unexpected adverse events were observed in any of the recipients. All 14 patients surviving in remission have robust trilineage hematopoiesis and are transfusion-free with a median follow-up of 277 days (range 139-964 days). Direct antagonism of CXCR4 by AMD3100 may provide a more rapid and possibly less toxic and cumbersome alternative to traditional G-CSF-based mobilization in normal donors. This trial was registered as #NCT00241358 at www.ClinicalTrials.gov CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A freeway to stem cells? Alois Gratwohl and Aleksandra Wodnar-Filipowicz Blood 2008 112: 923-924. [Full Text] [PDF] This article has been cited by other articles: K. Holig, M. Kramer, F. Kroschinsky, M. Bornhauser, T. Mengling, A. H. Schmidt, C. Rutt, and G. Ehninger Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors Blood, October 29, 2009; 114(18): 3757 - 3763. [Abstract] [Full Text] [PDF] J. Skokowa, J. P. Fobiwe, L. Dan, B. K. Thakur, and K. Welte Neutrophil elastase is severely down-regulated in severe congenital neutropenia independent of ELA2 or HAX1 mutations but dependent on LEF-1 Blood, October 1, 2009; 114(14): 3044 - 3051. [Abstract] [Full Text] [PDF] R. E. Donahue, P. Jin, A. C. Bonifacino, M. E. Metzger, J. Ren, E. Wang, and D. F. Stroncek Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures Blood, September 17, 2009; 114(12): 2530 - 2541. [Abstract] [Full Text] [PDF] P. Ramirez, M. P. Rettig, G. L. Uy, E. Deych, M. S. Holt, J. K. Ritchey, and J. F. DiPersio BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells Blood, August 13, 2009; 114(7): 1340 - 1343. [Abstract] [Full Text] [PDF] A. M. Boehmler, A. Drost, L. Jaggy, G. Seitz, T. Wiesner, C. Denzlinger, L. Kanz, and R. Mohle The CysLT1 Ligand Leukotriene D4 Supports {alpha}4{beta}1- and {alpha}5{beta}1-Mediated Adhesion and Proliferation of CD34+ Hematopoietic Progenitor Cells J. Immunol., June 1, 2009; 182(11): 6789 - 6798. [Abstract] [Full Text] [PDF] A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting Blood, May 7, 2009; 113(19): 4604 - 4613. [Abstract] [Full Text] [PDF] M. A. Schroeder, M. P. Rettig, P. Ramirez, and J. F. DiPersio Optimal Mobilization of Normal and Leukemic Stem Cells via Modulation of Chemokine and Integrin Axes Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 15 - 22. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020